title: Is ticlopidine more effective than aspirin in preventing adverse cardiovascular events after myocardial infarction (MI)?
authors.affiliation: University of Washington, Family Medicine REsidency, Harborview Medical Center, Seattle, USA. olsonjc@u.washington.edu
authors.forename: J
authors.initials: J
authors.lastname: Olson
authors.forename: J
authors.initials: J
authors.lastname: Huntington
mesh_terms: D000787:Angina Pectoris / Q000517:prevention & control*; D001241:Aspirin / Q000627:therapeutic use*; D004311:Double-Blind Method; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000517:prevention & control*; D013988:Ticlopidine / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin